Aisling Capital
PE / VC
2000
$1 800 M
New York, New York, United States
Investment Ticket
Investment Horizon
Investment Stage
Exit Strategy
Profile
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Industry
Region of investment
Aisling Capital Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Aisling Capital IV
|
Venture Capital (VC)
|
Healthcare Services
Medical Devices
Life Sciences
|
Seed
Series A
|
North America
|
$5-10 m
|
$280 M
|
November 2017
|
|
Aisling Capital Fund V
|
Venture Capital (VC)
|
Healthcare Services
Medical Devices
Life Sciences
|
Seed
Series A
|
North America
|
$5-10 m
|
$144 M
|
June 2020
|
|
Aisling Capital I, L.P.
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
Pharmaceuticals
Life Sciences
|
Pre-seed
Seed
|
North America
|
$5-10 m
|
$30 M
|
January 2013
|
|
Aisling Capital II
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
Pharmaceuticals
Life Sciences
|
Pre-seed
Seed
|
North America
|
$5-10 m
|
$550 M
|
August 2015
|
